101 related articles for article (PubMed ID: 8987165)
1. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease.
Rydzewski A; Urano T; Hachiya T; Kaneko H; Baba S; Takada Y; Takada A
Thromb Res; 1996 Dec; 84(6):445-52. PubMed ID: 8987165
[TBL] [Abstract][Full Text] [Related]
2. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
3. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Nakamura K; Kariyazono H; Masuda H; Sakata R; Yamada K
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):391-7. PubMed ID: 11505083
[TBL] [Abstract][Full Text] [Related]
4. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans.
Pietraszek MH; Choudhury NA; Baba S; Sakaguchi S; Hachiya T; Urano T; Takada Y; Takada A
Int Angiol; 1993 Mar; 12(1):9-12. PubMed ID: 8376917
[TBL] [Abstract][Full Text] [Related]
5. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.
Nakamura K; Kariyazono H; Moriyama Y; Toyohira H; Kubo H; Yotsumoto G; Taira A; Yamada K
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):513-9. PubMed ID: 10636463
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic analysis of antiplatelet effect of sarpogrelate hydrochloride and its application to drug dosage regimen--modeling based on reversible inhibition of 5-HT2 serotonergic receptor in the platelet membrane by sarpogrelate hydrochloride and its metabolite].
Shimizu T; Yamada Y; Tashita A; Yamamoto K; Kotaki H; Sawada Y; Iga T
Yakugaku Zasshi; 1999 Nov; 119(11):850-60. PubMed ID: 10590712
[TBL] [Abstract][Full Text] [Related]
7. Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
Satomura K; Takase B; Hamabe A; Ashida K; Hosaka H; Ohsuzu F; Kurita A
Clin Cardiol; 2002 Jan; 25(1):28-32. PubMed ID: 11808836
[TBL] [Abstract][Full Text] [Related]
8. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Kajiwara I; Soejima H; Miyamoto S; Ogawa H
Thromb Res; 2011 Dec; 128(6):547-51. PubMed ID: 21722942
[TBL] [Abstract][Full Text] [Related]
9. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
11. The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium.
Houkin K; Nakayama N; Nonaka T; Koyanagi I
J Int Med Res; 2006; 34(1):65-72. PubMed ID: 16604825
[TBL] [Abstract][Full Text] [Related]
12. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064
[TBL] [Abstract][Full Text] [Related]
13. Enhanced platelet response to serotonin in Buerger's disease.
Pietraszek MH; Choudhury NA; Koyano K; Sakaguchi S; Kamiya T; Urano T; Takada Y; Takada A
Thromb Res; 1990 Nov; 60(3):241-6. PubMed ID: 2084953
[No Abstract] [Full Text] [Related]
14. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
15. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
Umrani DN; Bodiwala DN; Goyal RK
Mol Cell Biochem; 2003 Jul; 249(1-2):53-7. PubMed ID: 12956398
[TBL] [Abstract][Full Text] [Related]
16. The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients.
Ogawa S; Takeuchi K; Sugimura K; Sato C; Fukuda M; Lee R; Ito S; Sato T
Clin Exp Pharmacol Physiol; 1999; 26(5-6):461-4. PubMed ID: 10386239
[TBL] [Abstract][Full Text] [Related]
17. Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT
Kubacka M; Kazek G; Kotańska M; Filipek B; Waszkielewicz AM; Mogilski S
Eur J Pharmacol; 2018 Jan; 818():263-270. PubMed ID: 29111111
[TBL] [Abstract][Full Text] [Related]
18. A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Satoh K; Yatomi Y; Ozaki Y
J Thromb Haemost; 2006 Feb; 4(2):479-81. PubMed ID: 16420586
[No Abstract] [Full Text] [Related]
19. Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation.
Kim TE; Kim JR; Jung JA; Kim SR; Lee JW; Jun H; Lee SY; Huh W; Ko J
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):114-9. PubMed ID: 23073143
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
Kodama A; Komori K; Kajikuri J; Itoh T
J Vasc Surg; 2009 Sep; 50(3):617-25. PubMed ID: 19700096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
